> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Aurobindo Recalls Ranitidine Products
- URL: https://www.fdaweb.com/aurobindo-recalls-ranitidine-products/
- Published: 2019-11-08T12:00:00.000Z
- Updated: 2026-09-14T15:52:34.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5145461

Aurobindo is [recalling](https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine?ref=fdaweb.com) 38 lots of over-the-counter ranitidine tablets (150 mg), Rx ranitidine capsules (150 mg and 300 mg), and ranitidine syrup (15mg/mL). An FDA [notice](https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-and-press-announcements-ndma-zantac-ranitidine?ref=fdaweb.com) says the medications contain unacceptable levels of N-nitrosodimethylamine (NDMA). The notice says FDA has advised companies to recall their ranitidine if testing shows NDMA levels about the acceptable daily intake of 96 nanograms per day or 0.32 parts per million for ranitidine.